glp-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 Receptor Agonists for Obesity

[55] Medication-based treatment may be preferred when patients decline surgery, have lower surgical risk thresholds, require reversible treatment, or need cardiometabolic risk reduction without anatomic intervention

Sermorelin body composition changes: Measurable shifts in lean muscle mass and body fat percentage generally appear between eight and twelve weeks

Pickart & Margolina 2014 Chelates free copper, reduces oxidative damage, and upregulates superoxide dismutase the body's primary antioxidant enzyme

GLP-1 (Glucagon-Like Peptide-1) is a hormone released from the gut after eating

Many traditional removal and shaping methods are highly invasive, but not our body contouring procedure